Biotech executive Raymond Stevens, Ph.D., recalls the public biotech market of 2013, when a lot of companies were “wondering and waiting,” biding their time and assessing their value as recovery from the 2008 housing crisis dragged on. The way he remembers it, “the market had been closed.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,